Two important studies analysed the types of colon cancers that responded to aspirin treatment, and discovered that only a subset of tumours were sensitive: those containing activating mutations of PI3KCA45, 46, which results in a constitutively upregulated PI3K/Akt/mTOR pathway. This evidence concerns the gene AKT1 and malignant colon neoplasm.